News
MGNX
5.50
+4.76%
0.25
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at MGNX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at MGNX last week (0708-0712)?
Weekly Report · 07/15 09:04
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
MacroGenics (NASDAQ:MGNX) has ramped up its cash burn by 155% in the last year. The company's operating revenue is down by 74% and the company is spending heavily to fund its growth. In March 2024, MacroGenics had US$184m in cash and was debt-free. But the company's cash burn equates to 43% of its market value. We think shareholders should be worried about its cash runway for the company. Simply Wall St. Has identified 4 warning signs for Macrogenics that you should know about.
Simply Wall St · 07/12 11:45
Weekly Report: what happened at MGNX last week (0701-0705)?
Weekly Report · 07/08 09:04
Weekly Report: what happened at MGNX last week (0624-0628)?
Weekly Report · 07/01 09:04
Weekly Report: what happened at MGNX last week (0617-0621)?
Weekly Report · 06/24 09:05
Weekly Report: what happened at MGNX last week (0610-0614)?
Weekly Report · 06/17 09:04
MacroGenics Insider Ups Holding By 83% During Year
Insiders were net buyers of MacroGenics, Inc.'s stock in the last year. The biggest single purchase by an insider was when Edward Hurwitz bought US$74k worth of shares at a price of US$4.91 per share. In the last 12 months,  insiders have bought more shares in the company than they sold.  MacroGenics insiders own 2.7% of the company. You can see the insider transactions of Macrogenics over the lastyear.
Simply Wall St · 06/12 10:13
MacroGenics to Participate in Upcoming Investor Conference
Barchart · 06/11 06:45
Weekly Report: what happened at MGNX last week (0603-0607)?
Weekly Report · 06/10 09:04
MILLENNIUM MANAGEMENT LLC REPORTS 5.1% PASSIVE STAKE IN MACROGENICS INC AS OF JUNE 3 - SEC FILING
Reuters · 06/04 20:54
Buy Rating Affirmed for MacroGenics Amidst Promising Oncology Pipeline and Strategic Positioning
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on MacroGenics (MGNX – Research Report) and kept the price target at $18.00. The company is developing a next-generation B7-H3 targeted antibody-drug conjugates.
TipRanks · 06/03 23:45
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
SAIC shares dipped 11% to $119.91 following first-quarter results. GameStop Corp. Shares climbed 34.5% after Roaring Kitty on a Reddit post, shared his position on the stock. Microbot Medical Inc. Shares jumped 92.5%; Bio-Path Holdings, Inc. Jumped 75%.
Benzinga · 06/03 17:56
Monday Sector Leaders: Biotechnology, Drugs
NASDAQ · 06/03 15:59
MacroGenics (MGNX) Gets a Hold from TD Cowen
TipRanks · 06/03 11:36
Weekly Report: what happened at MGNX last week (0527-0531)?
Weekly Report · 06/03 09:05
Weekly Report: what happened at MGNX last week (0520-0524)?
Weekly Report · 05/27 09:05
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Macrogenics has 14 analysts' ratings that vary from bullish to bearish over the last quarter. The company has a 12-month price target of $.
Benzinga · 05/24 18:00
Macrogenics Is Maintained at Buy by BTIG
Dow Jones · 05/24 17:11
More
Webull provides a variety of real-time MGNX stock news. You can receive the latest news about Macrogenics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.